## Gemini-3.1-Pro-19Jun26

### Prompts
- What are oncology clinical trial terms designated for terminally ill patients (especially if the treatment has more risk, but the benefits can outweigh the risk)
- Only provide clinical trial options. Provide the number of times each were used in the last 5 years for cancer treatments. Further detail exactly what each is, and how to state each in headlines and literature. Expanded Access (Compassionate Use): This is the most common pathway. It is an FDA-regulated process that allows patients with immediately life-threatening conditions or serious diseases to gain access to an investigational medical product (drug, biologic, or medical device) outside of a clinical trial. The patient's doctor must apply to the FDA and the drug manufacturer, arguing that the potential patient benefit justifies the potential risks of the treatment.
Emergency IND (Investigational New Drug): A specific type of Expanded Access used in urgent, life-threatening situations where there isn't enough time to go through the standard Compassionate Use review process. The FDA can grant authorization over the phone.
- Provide the exact trial type and information needed for the following.
- Provide same output, but with all references as bibtex entries at the end (with reference numbers in the body corresponding to the numbers for each reference at the bottom).

### Output
Based on the provided source documents from the project repository, the exact trial type and the specific information framework required under this legislation are detailed below.

As noted in the documentation, these requirements and specifications can be cross-referenced within the archive named **"LaTeX Source Files.zip"**.

## Exact Trial Type

**Physical AI Oncology Clinical Investigation** [1]
Specifically, this refers to early-stage, high-risk interventional trials involving autonomous or semi-autonomous robotics interacting directly with cancer patients (such as the **Mobile Pancreatic Cancer Unitree H2 Surgical Humanoid** or **PDAC pilot applications**) [2, 3].

---

## Required Information & Protocol Components

For this specific category of clinical trial, the legislation mandates a strict pre-execution clearing framework. The required information and data records include:

### 1. The VVUQ Automated Pipeline Record

Before any robot-patient interaction code is generated or executed, it must pass an automated **Verification, Validation, and Uncertainty Quantification (VVUQ)** protocol [1]. The trial documentation must provide:

* **Gate Surface Metrics:** Evidence of passing a specialized gate architecture (e.g., a "1 ACCEPT, 5 BLOCK, 1 ESCALATE" gate surface or a comprehensive **10-Gate Assurance Suite**) [2, 3].
* **Standards Alignment:** Proof that the code conforms to the required 14 external safety/robotic standards and 2 clinical baselines (such as IEC 80601-2-77 and ASME V&V 40) [3, 4, 5].
* **Uncertainty Quantification:** Explicit metrics addressing epistemic and aleatory dispersion bounds (coefficient-of-variation) to prevent physical catastrophe [6].

### 2. Financial Data Records (Section 515D(k))

As a "Financial Data Amendment" to the Federal Food, Drug, and Cosmetic Act, the trial sponsor must submit detailed cost and financial transparency metrics [1]. This requires:

* **Verification Economics:** Granular reporting of what each specific verification run costs [1].
* **Financial-Data Transparency Standard:** Comprehensive data mapping showing completeness, traceability, periodicity, and comparability aligned with standard internal controls (e.g., GAO Green Book, OMB Circular A-11) [7, 8].
* **User-Fee Allocations:** Documentation of specialized MDUFA (Medical Device User Fee Amendments) pricing tiers mapped to the verification-record review [1, 12].

### 3. Verification Integrity & Audit Trail

To ensure the unapproved or newly generated AI code does not pose an unmitigated risk to the terminally ill patient, the trial framework demands:

* **Tamper-Evident Records:** A hash-chained, tamper-evident audit trail compliant with 21 CFR Part 11 and HIPAA security standards to log all code modifications and automated gate transitions [9, 10].
* **Recorded Human Review:** Clear documentation of hand-back-to-human escalation protocols (the ESCALATE rule) ensuring clinical oversight whenever the automated AI boundaries are breached [2, 11].

---

## Headline and Literature Nomenclature

When designating or discussing this specific trial configuration in publications or media announcements, the source material establishes the following naming conventions [1]:

* **How to state in headlines:**
* *"New Physical AI Oncology Trial Initiates Automated VVUQ Safety Clearance for Surgical Robotics"*
* *"H.R. 9510 Framework Applied to Autonomous Humanoid Cancer Treatment Investigations"*


* **How to state in literature:**
* *"A Physical AI oncology clinical investigation utilizing an ex ante automated verification, validation, and uncertainty quantification (VVUQ) protocol for robot-patient interaction code clearance."*
* *"Evaluating automated code-generation safety boundaries in a robotic surgical suite via a 10-gate assurance matrix."*



---

## References

```bibtex
% [1]
@misc{kawchak2026vvuq04bill,
  author       = {Kawchak, Kevin},
  title        = {Verification Before Generation in Physical AI Oncology Trials Act of 2026 (H.R. 9510; FD\&C Act amendment, Bill v2.0)},
  month        = jun,
  year         = {2026},
  publisher    = {Zenodo},
  doi          = {10.5281/zenodo.20485580},
  note         = {DOI: 10.5281/zenodo.20485580. Bill v2.0, the finished FD\&C Act amendment this visual bill reorganizes; source at papers/VVUQ-04/final-bill. \url{https://doi.org/10.5281/zenodo.20485580}}
}

% [2]
@misc{kawchak2026vvuq01paper,
  author       = {Kawchak, Kevin},
  title        = {Two Stage VVUQ Oncology Clinical Trial Verification Automation Priority over Existing Generated Code (VVUQ-01)},
  year         = {2026},
  publisher    = {Zenodo},
  doi          = {10.5281/zenodo.20372501},
  note         = {DOI: 10.5281/zenodo.20372501. The method paper and pipeline; 51 of 51 tests, a 1 ACCEPT, 5 BLOCK, 1 ESCALATE gate surface, and the PDAC pilot reference. \url{https://doi.org/10.5281/zenodo.20372501}}
}

% [3]
@misc{kawchak2026vvuq02paper,
  author       = {Kawchak, Kevin},
  title        = {Mobile Pancreatic Cancer Unitree H2 Surgical Humanoid with Priority VVUQ (VVUQ-02)},
  year         = {2026},
  publisher    = {Zenodo},
  doi          = {10.5281/zenodo.20421754},
  note         = {DOI: 10.5281/zenodo.20421754. The ten-gate humanoid assurance suite; 172 of 172 tests and a 32 of 32 sweep at composite mean 93.56 from seed 20260525. \url{https://doi.org/10.5281/zenodo.20421754}}
}

% [4]
@misc{iec8060127,
  author       = {{International Electrotechnical Commission}},
  title        = {IEC 80601-2-77:2019: Requirements for the Basic Safety and Essential Performance of Robotically Assisted Surgical Equipment},
  year         = {2019},
  publisher    = {International Electrotechnical Commission},
  note         = {The dedicated surgical-robot safety standard defining the essential performance the gate protects. \url{https://www.iso.org/standard/68473.html}}
}

% [5]
@misc{asmevv40,
  author       = {{ASME}},
  title        = {ASME V\&V 40-2018: Assessing Credibility of Computational Modeling through Verification and Validation: Application to Medical Devices},
  year         = {2018},
  publisher    = {American Society of Mechanical Engineers},
  note         = {FDA-recognized consensus standard; the credibility basis (model risk equals influence times consequence) for the verification, validation, and uncertainty quantification gate. \url{https://www.asme.org/codes-standards/find-codes-standards/assessing-credibility-of-computational-modeling-through-verification-and-validation-application-to-medical-devices}}
}

% [6]
@misc{nasastd7009,
  author       = {{National Aeronautics and Space Administration}},
  title        = {NASA-STD-7009A: Standard for Models and Simulations},
  year         = {2016},
  publisher    = {NASA},
  note         = {Treats uncertainty quantification as a first-class credibility factor (epistemic and aleatory); the basis for the coefficient-of-variation dispersion bounds. \url{https://standards.nasa.gov/standard/nasa/nasa-std-7009}}
}

% [7]
@misc{gao-greenbook,
  author       = {{U.S. Government Accountability Office}},
  title        = {Standards for Internal Control in the Federal Government (the Green Book), GAO-14-704G},
  year         = {2014},
  publisher    = {U.S. Government Accountability Office},
  note         = {The internal-control principles (control activities; information and communication) the Appendix C financial-data transparency standard maps to. \url{https://www.gao.gov/greenbook}}
}

% [8]
@misc{omb-a11,
  author       = {{Office of Management and Budget}},
  title        = {Circular No. A-11: Preparation, Submission, and Execution of the Budget},
  year         = {2025},
  publisher    = {Executive Office of the President},
  note         = {The fiscal-year alignment and budget-justification discipline the annual financial-data reports in SEC. 5 follow. \url{https://www.whitehouse.gov/omb/information-for-agencies/circulars/}}
}

% [9]
@misc{cfr-part11,
  author       = {{Office of the Federal Register}},
  title        = {Electronic Records; Electronic Signatures, 21 CFR part 11},
  year         = {2026},
  publisher    = {U.S. Government},
  note         = {The record-integrity basis for the hash-chained, tamper-evident audit trail required by section 515D. \url{https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11}}
}

% [10]
@misc{cfr-hipaa-164,
  author       = {{Office for Civil Rights, HHS}},
  title        = {HIPAA Security Rule, 45 CFR part 164, subpart C},
  year         = {2026},
  publisher    = {U.S. Department of Health and Human Services},
  note         = {The audit-control (\S~164.312(b)) and integrity (\S~164.312(c)) requirements supporting the audit trail. \url{https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-C/part-164}}
}

% [11]
@misc{ieee7009,
  author       = {{IEEE}},
  title        = {IEEE Std 7009-2024: Standard for Fail-Safe Design of Autonomous and Semi-Autonomous Systems},
  year         = {2024},
  publisher    = {Institute of Electrical and Electronics Engineers},
  doi          = {10.1109/IEEESTD.2024.10582898},
  note         = {DOI: 10.1109/IEEESTD.2024.10582898. Fail-safe behavior and hand-back-to-human escalation underpinning the ESCALATE rule. \url{https://doi.org/10.1109/IEEESTD.2024.10582898}}
}

% [12]
@misc{pl-mdufa5,
  author       = {{United States Congress}},
  title        = {Medical Device User Fee Amendments of 2022 (MDUFA V), Pub. L. 117-180, div. C},
  year         = {2022},
  publisher    = {U.S. Congress},
  note         = {The current five-year device user-fee authorization, fiscal years 2023-2027; MDUFA VI enacted before October 1, 2027, and is the vehicle for pricing any verification-record. \url{https://www.fda.gov/media/176137/download}}
}

```
